OverviewSuggest Edit

MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. The Company's lead product candidate, Afrezza, is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Afrezza is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream.

TypePublic
Founded1991
HQWestlake Village, CA, US
Websitemannkindcorp.com
Employee Ratings3.2
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)232(+4%)
Job Openings57
Revenue (FY, 2020)$65.1 M(+4%)
Share Price (Jul 2021)$4.1(-2%)
Cybersecurity ratingBMore

Key People/Management at MannKind Corporation

Michael Castagna

Michael Castagna

Chief Executive Officer, Director
Ronald Consiglio

Ronald Consiglio

Director
Kent Kresa

Kent Kresa

Chairman of the Board
Henry L. Nordhoff

Henry L. Nordhoff

Director
Patrick McCauley

Patrick McCauley

Chief Commercial Officer
David M. Kendall

David M. Kendall

Chief Medical Officer
Show more

MannKind Corporation Office Locations

MannKind Corporation has offices in Westlake Village and Danbury
Westlake Village, CA, US (HQ)
30930 Russell Ranch Rd #301
Danbury, CT, US
1 Casper St
Show all (2)

MannKind Corporation Financials and Metrics

MannKind Corporation Revenue

Embed Graph
View revenue for all periods
MannKind Corporation's revenue was reported to be $65.14 m in FY, 2020
USD

Revenue (FY, 2020)

65.1m

Gross profit (FY, 2020)

50.1m

Gross profit margin (FY, 2020), %

76.8%

Net income (FY, 2020)

(57.2m)

EBIT (FY, 2020)

(47.9m)

Market capitalization (30-Jul-2021)

1.0b

Closing stock price (30-Jul-2021)

4.1

Cash (31-Dec-2020)

67.0m

EV

964.8m
MannKind Corporation's current market capitalization is $1 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

11.7m27.9m63.0m65.1m

Revenue growth, %

(93%)137%126%

Cost of goods sold

17.2m19.4m20.1m15.1m

Gross profit

(5.5m)8.5m43.0m50.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

3.5m3.9m4.5m17.4m15.0m14.6m16.2m15.1m15.4m

Cost of goods sold

4.0m5.1m5.3m4.0m4.3m7.1m4.2m3.7m3.6m

Gross profit

(543.0k)(1.2m)(834.0k)13.4m10.7m7.5m12.1m11.4m11.8m

Gross profit Margin, %

(16%)(31%)(19%)77%71%51%74%76%77%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

43.9m71.2m29.9m67.0m

Accounts Receivable

2.8m4.0m3.5m4.2m

Prepaid Expenses

3.0m2.6m2.9m3.1m

Inventories

2.7m3.6m4.2m5.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

26.7m26.2m10.4m34.5m8.0m30.2m38.9m63.2m52.4m

Accounts Receivable

1.6m2.8m2.8m3.8m5.0m4.1m5.0m3.4m4.1m

Prepaid Expenses

2.4m2.6m3.0m2.4m2.7m3.6m1.9m1.9m4.6m

Inventories

3.9m3.7m2.8m3.7m4.0m3.7m3.2m3.8m4.9m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(117.3m)(87.0m)(51.9m)(57.2m)

Depreciation and Amortization

3.5m2.9m972.0k2.1m

Inventories

(3.3m)(3.2m)(558.0k)(1.3m)

Accounts Payable

3.8m(1.6m)(593.0k)793.0k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(30.4m)(53.1m)(77.2m)(14.9m)(27.3m)(37.6m)(9.3m)(19.6m)(30.8m)

Depreciation and Amortization

706.0k1.5m2.5m367.0k739.0k407.0k538.0k1.1m1.6m

Inventories

(1.8m)(1.8m)(1.9m)(123.0k)(366.0k)(95.0k)428.0k(164.0k)(1.2m)

Accounts Payable

(2.0m)2.3m(1.2m)1.6m2.2m6.3m1.9m1.0m1.0m
USDFY, 2017

Revenue/Employee

47.0k

Debt/Equity

-0.4 x

Debt/Assets

0.9 x

Financial Leverage

-0.4 x
Show all financial metrics

MannKind Corporation Operating Metrics

FY, 2017FY, 2018FY, 2019

Patents Issued

9301.02 k

Patents Issued (Afrezza)

530570600

Patent Applications

280240

Patent Applications (Afrezza)

200160125
Show all operating metrics

MannKind Corporation Revenue Breakdown

Embed Graph

MannKind Corporation revenue breakdown by business segment: 40.1% from Commercial Product Sales and 59.9% from Collaboration

MannKind Corporation Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

MannKind Corporation Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

MannKind Corporation Online and Social Media Presence

Embed Graph

MannKind Corporation Company Culture

  • Overall Culture

    A+

    85/100

  • CEO Rating

    A+

    84/100

  • Compensation

    A+

    93/100

  • Diversity

    B+

    81/100

Learn more on Comparably

MannKind Corporation News and Updates

MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference

WESTLAKE VILLAGE, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michae…

MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference

WESTLAKE VILLAGE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael…

MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021

WESTLAKE VILLAGE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 12, …

MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Micha…

MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference

WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Micha…

MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering

WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") in a private placement (the "offering") to qualified institutional buye…
Show more

MannKind Corporation Blogs

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th Content Import Thu, 07/29/2021 - 11:01 INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th …

MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29

- Poster 923-P: Phase 2 clinical study results revealed similar tolerability and time-action profile of Technosphere® Insulin in pediatric subjects as in published data for adults; provides rationale for conducting a Phase 3 study - Poster 722-P: Data shared that Technosphere Insulin improved

MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5

Post hoc analysis of the STAT study shows that Technosphere® insulin reduced nocturnal hypoglycemia compared to insulin aspart in adult patients with T1D WESTLAKE VILLAGE, Calif. , June 3, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th

Indiana native living with Type 1 diabetes is sharing an inspirational message to kick off Indy 500 week WESTLAKE VILLAGE, Calif. and INDIANAPOLIS , May 20, 2021 /PRNewswire/ --  MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly , who is living with Type 1

MannKind Corporation Reports 2021 First Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% senior convertible notes $278.3 million of Cash, Cash Equivalents and Investments at March 31, 2021 Tyvaso DPI™  NDA submitted to the FDA by

MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.

Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product WESTLAKE VILLAGE, Calif. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation   (N asdaq :   MNKD) today announced that it has acquired QrumPharma, Inc.
Show more

MannKind Corporation Frequently Asked Questions

  • When was MannKind Corporation founded?

    MannKind Corporation was founded in 1991.

  • Who are MannKind Corporation key executives?

    MannKind Corporation's key executives are Michael Castagna, Ronald Consiglio and Kent Kresa.

  • How many employees does MannKind Corporation have?

    MannKind Corporation has 232 employees.

  • What is MannKind Corporation revenue?

    Latest MannKind Corporation annual revenue is $65.1 m.

  • What is MannKind Corporation revenue per employee?

    Latest MannKind Corporation revenue per employee is $280.8 k.

  • Who are MannKind Corporation competitors?

    Competitors of MannKind Corporation include Amgen, Assertio and Lexicon Pharmaceuticals.

  • Where is MannKind Corporation headquarters?

    MannKind Corporation headquarters is located at 30930 Russell Ranch Rd #301, Westlake Village.

  • Where are MannKind Corporation offices?

    MannKind Corporation has offices in Westlake Village and Danbury.

  • How many offices does MannKind Corporation have?

    MannKind Corporation has 2 offices.